Four-Person Biotech Makes Huge Deal with Novartis

Apr 07, 2017

Boston Business Journal

Lubris BioPharma, a four-person, privately held biotech in Framingham, Mass., has struck a licensing deal with Novartis for a dry-eye treatment known as ECF843 that could generate as much as $1 billion in total payments and royalties.

Novartis and Lubris did not disclose the financial terms. But an article in the Boston Business Journal reported that sources said the upfront payment to Lubris, combined with potential milestone payments and royalties if the drug hits the market, has the potential to surpass $1 billion.

Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments